Question 1

Capillary leak syndrome during interleukin therapy may result in which problem?

Accepted Answer

A) Renal failure 
B) Asthma 
C) Ecchymosis 
D) Heart failure 
A) Renal failure 
B) Asthma 
C) Ecchymosis 
D) Heart failure D

Question 2

A female patient is being treated with biological response-modifying drugs.After the completion of her treatment,she should be cautioned to avoid pregnancy for what time period?

Accepted Answer

A) 6 months 
B) 12 months 
C) 18 months 
D) 24 months 
A) 6 months 
B) 12 months 
C) 18 months 
D) 24 months D

Question 3

A patient with end-stage renal failure has been admitted to hospital for severe anemia but is refusing blood transfusions.Which drugs will likely be used to stimulate the production of red blood cells (RBCs)?

Accepted Answer

A) filgrastim (Neupogen) 
B) interferon 
C) epoetin alfa (Eprex) 
D) sargramostim (Leukine) 
A) filgrastim (Neupogen) 
B) interferon 
C) epoetin alfa (Eprex) 
D) sargramostim (Leukine) C

Question 4

Which medication is indicated in the treatment of rheumatoid arthritis?

Accepted Answer

A) thalidomide (Thalomid) 
B) tretinoin (Vesanoid) 
C) bacillus Calmette-Guérin (BCG) vaccine (Immuncyst) 
D) etanercept (Enbrel) 
A) thalidomide (Thalomid) 
B) tretinoin (Vesanoid) 
C) bacillus Calmette-Guérin (BCG) vaccine (Immuncyst) 
D) etanercept (Enbrel)

Question 5

When providing patient education related to biological response-modifying drugs,which is important information to give the patient?

Accepted Answer

A) Interleukins cannot be self-administered. 
B) Any temperature higher than 39.5°C needs to be reported to the health care provider. 
C) Pregnancy should be avoided for 6 months. 
D) Adverse effects usually disappear within 72 to 96 hours after therapy is discontinued. 
A) Interleukins cannot be self-administered. 
B) Any temperature higher than 39.5°C needs to be reported to the health care provider. 
C) Pregnancy should be avoided for 6 months. 
D) Adverse effects usually disappear within 72 to 96 hours after therapy is discontinued.

Question 6

A patient is receiving interferon therapy.What expected adverse effect should the nurse tell this patient about?

Accepted Answer

A) Anemia 
B) Increased appetite 
C) Constipation 
D) Flulike effects 
A) Anemia 
B) Increased appetite 
C) Constipation 
D) Flulike effects

Question 7

Lymphokine-activated killer (LAK)cells,which multiply as a result of interleukin therapy,do what?

Accepted Answer

A) They directly inhibit deoxyribonucleic acid (DN
A)  and protein synthesis. 
B) They destroy cancer cells and ignore normal cells. 
C) They destroy cancer cells by destroying all types of cells. 
D) They prevent virus replication and prevent viruses from penetrating healthy cells. 
A) They directly inhibit deoxyribonucleic acid (DN
A)  and protein synthesis. 
B) They destroy cancer cells and ignore normal cells. 
C) They destroy cancer cells by destroying all types of cells. 
D) They prevent virus replication and prevent viruses from penetrating healthy cells.

Question 8

A patient is to take antineoplastic therapy with monoclonal antibodies such as rituximab (Rituxan).The nurse should carefully assess this patient for which condition?

Accepted Answer

A) Anorexia 
B) Neuropathy 
C) Respiratory problems 
D) Heart failure 
A) Anorexia 
B) Neuropathy 
C) Respiratory problems 
D) Heart failure

Question 9

Which is an effect of colony-stimulating factors (CSFs)?

Accepted Answer

A) Multiplication of T cells 
B) Decreased neutrophil counts 
C) Increased cytotoxic activity of natural killer (NK) cells 
D) Stimulation of certain immune cells 
A) Multiplication of T cells 
B) Decreased neutrophil counts 
C) Increased cytotoxic activity of natural killer (NK) cells 
D) Stimulation of certain immune cells

Question 10

Which is true in regard to therapy with interferon drugs?

Accepted Answer

A) Dosages should be administered in the morning. 
B) The patient should be encouraged to drink up to 2 to 3 L of fluids per day while taking these medications. 
C) To minimize allergic reactions, oral dosing is preferred. 
D) Shake the drug vial well before drawing up a dose. 
A) Dosages should be administered in the morning. 
B) The patient should be encouraged to drink up to 2 to 3 L of fluids per day while taking these medications. 
C) To minimize allergic reactions, oral dosing is preferred. 
D) Shake the drug vial well before drawing up a dose.

Exam 54: Biological Response–Modifying Drugs

Capillary leak syndrome during interleukin therapy may result in which problem?

A female patient is being treated with biological response-modifying drugs.After the completion of her treatment,she should be cautioned to avoid pregnancy for what time period?

A patient with end-stage renal failure has been admitted to hospital for severe anemia but is refusing blood transfusions.Which drugs will likely be used to stimulate the production of red blood cells (RBCs)?

Which medication is indicated in the treatment of rheumatoid arthritis?

When providing patient education related to biological response-modifying drugs,which is important information to give the patient?

A patient is receiving interferon therapy.What expected adverse effect should the nurse tell this patient about?

Lymphokine-activated killer (LAK)cells,which multiply as a result of interleukin therapy,do what?

A patient is to take antineoplastic therapy with monoclonal antibodies such as rituximab (Rituxan).The nurse should carefully assess this patient for which condition?

Which is an effect of colony-stimulating factors (CSFs)?

Which is true in regard to therapy with interferon drugs?

Nursing Practice in Canada and Drug Therapy

Pharmacological Principles

Legal and Ethical Considerations

Patient Focused Considerations

Gene Therapy and Pharmacogenomics

Medication Errors: Preventing and Responding

Patient Education and Drug Therapy

Over-the-Counter Drugs and Natural Health Products

Vitamins and Minerals

Principles of Drug Administration

Analgesic Drugs

General and Local Anaesthetics

Central Nervous System Depressants and Muscle Relaxants

Central Nervous System Stimulants and Related Drugs

Antiepileptic Drugs

Antiparkinsonian Drugs

Psychotherapeutic Drugs

Substance Misuse

Adrenergic Drugs

Adrenergic-Blocking Drugs

Cholinergic Drugs

Cholinergic-Blocking Drugs

Antihypertensive Drugs

Antianginal Drugs

Heart Failure Drugs

Antidysrhythmic Drugs

Coagulation Modifier Drugs

Antilipemic Drugs

Diuretic Drugs

Fluids and Electrolytes

Pituitary Drugs

Thyroid and Antithyroid Drugs

Antidiabetic Drugs

Adrenal Drugs

Women’s Health Drugs

Men’s Health Drugs

Antihistamines,Decongestants,Antitussives,and Expectorants

Respiratory Drugs

Acid-Controlling Drugs

Antidiarrheal Drugs and Laxatives

Antiemetic and Anti-nausea Drugs

Nutritional Supplements

Antibiotics, Part 1: Sulfonamides, Penicillins, Cephalosporins, Macrolides, and Tetracyclines

Antibiotics Part 2: Aminoglycosides, Fluoroquinolones, and Other Drugs

Antiviral Drugs

Antitubercular Drugs

Antifungal Drugs

Antimalarial, Antiprotozoal, and Anthelmintic Drugs

Anti-Inflammatory and Antigout Drugs

Immunosuppressant Drugs

Immunizing Drugs and Pandemic Preparedness

Antineoplastic Drugs Part 1: Cancer Overview and Cell Cycle–Specific Drugs

Antineoplastic Drugs Part 2: Cell Cycle–Nonspecific and Miscellaneous Drugs

Anemia Drugs

Dermatological Drugs

Ophthalmic Drugs

Otic Drugs

Filters